What the FDA labels say about taking them together
Methylprednisolone and ublituximab
Ublituximab's FDA label of February 19, 2026 names methylprednisolone in its warnings and precautions section; the methylprednisolone labels PlainMeds reads (3) do not name ublituximab. The ublituximab label: “In Studies 1 and 2, patients received methylprednisolone (or an equivalent steroid), an antihistamine, and possibly other pre-medication (i.e., acetaminophen) to reduce the risk of infusion reactions prior to each …”
Check it at the source: the methylprednisolone FDA label on DailyMed (effective June 22, 2026, Mylan Pharmaceuticals Inc.); the ublituximab FDA label on DailyMed (effective February 19, 2026).
What does the methylprednisolone label say about ublituximab?
Methylprednisolone's label (effective June 22, 2026) and its 2 other brand-application labels do not name ublituximab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Methylprednisolone), NDA011153 (Pfizer), as published by Mylan Pharmaceuticals Inc., effective June 22, 2026 (SPL set 22dd75d6-f89a-44f7-8ca6-b64c4e9806dd), via openFDA; the full label on DailyMed
What does the ublituximab label say about methylprednisolone?
Ublituximab label, warnings and precautionsIn Studies 1 and 2 [see Clinical Studies (14) ], patients received methylprednisolone (or an equivalent steroid), an antihistamine, and possibly other pre-medication (i.e., acetaminophen) to reduce the risk of infusion reactions prior to each infusion.
Source: FDA drug label (BRIUMVI), TG Therapeutics, Inc., effective February 19, 2026 (SPL set 3a77cd8c-811b-407c-9140-d0c5c26435c2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methylprednisolone | Ublituximab | |
|---|---|---|
| Labeled for | Osteoarthritis, Allergies, Herpes and shingles, Leukemia, lymphoma and myeloma, Crohn's disease and ulcerative colitis, Multiple sclerosis, Asthma, Eczema (atopic dermatitis), Anemia | Multiple sclerosis |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.121 per tablet 4 mg tablet | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once